|
| Press Releases |
|
 |
|
| Wednesday, May 23, 2018 |
|
|
Eisai and Purdue Pharma to Present Latest Phase I Clinical Data on Lemborexant at 32nd Annual Sleep Meeting |
| Eisai Co., Ltd. and Purdue Pharma L.P. today announced they will present the latest data from two key Phase I clinical studies (Study 108 and Study 106). more info >> |
|
| Thursday, May 17, 2018 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate will be presented during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 1 to 5, 2018. more info >> |
|
| Monday, April 23, 2018 |
|
|
エーザイ、非オピオイド系重度慢性疼痛治療薬「Prialt(R)」に関する権利をRiemser社に譲渡 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、非オピオイド系重度慢性疼痛治療薬「Prialt(R)」（一般名：ziconotide acetate、以下 「Prialt」）の欧州における独占的開発権および販売権を Riemser Pharma GmbH （本社：ドイツ ベルリン、CEO: Konstantin von Alvensleben、以下 Riemser 社）に対して譲渡する契約を締結しましたのでお知らせします。 more info >> |
|
|
Eisai: Rights to Non-Opiod Severe Chronic Pain Treatment Prialt Transferred to Riemser |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive development and marketing rights for the non-opioid severe chronic pain treatment Prialt (ziconotide acetate) in Europe to Riemser Pharma GmbH. more info >> |
|
| Friday, April 20, 2018 |
|
|
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting |
| Eisai Co., Ltd. announced today that the latest data on its antiepileptic drugs (AED) perampanel and rufinamide will be presented at the 2018 Annual American Academy of Neurology (AAN) Meeting to be held from April 21 to 27, 2018 in Los Angeles, California in the United States. more info >> |
|
|
エーザイ、米国神経学会年次総会にてペランパネルおよびルフィナミドに関する最新データを発表 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、2018年4月21日から27日まで米国カリフォルニア州ロサンゼルスで開催される「米国神経学会（American Academy of Neurology）年次総会：AAN2018」において、抗てんかん剤ペランパネル（製品名「フィコンパ(R)」、英名「Fycompa(R)」）、およびルフィナミド（製品名「イノベロン(R)」、米国製品名「Banzel(R)」）に関する最新データを発表しますのでお知らせします。 more info >> |
|
| Thursday, April 19, 2018 |
|
|
エーザイ・EAファーマ・持田製薬、世界初の胆汁酸トランスポーター阻害剤「グーフィス錠5mg」を新発売 |
| エーザイ株式会社とその消化器事業子会社であるEAファーマ株式会社ならびに持田製薬株式会社は、胆汁酸トランスポーター阻害剤「グーフィス(R)錠5mg」（一般名：エロビキシバット水和物、開発番号：AJG533、以下「グーフィス(R)錠」）について、4月18日付けで薬価基準に収載されたことを受け、本日、EAファーマと持田製薬が新発売したことをお知らせいたします。 more info >> |
|
|
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan |
| Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. today announced that the bile acid transporter inhibitor "GOOFICE 5mg Tablet" was listed in Japan's National Health Insurance Drug Price List, and EA Pharma and Mochida launched the product onto Japan's market today. more info >> |
|
| Friday, April 13, 2018 |
|
|
エーザイ、新規結核治療薬の開発に向けてブロード研究所・コロラド州立大学・シカゴ大学と共同研究契約を締結 |
| エーザイ株式会社は、このたび、ブロード研究所、コロラド州立大学のマイコバクテリア研究所、シカゴ大学と、新規結核治療薬の開発に向けた共同研究契約を締結しましたのでお知らせします。 more info >> |
|
|
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago |
| Eisai Co., Ltd. announced today that it has entered into a joint research agreement with the Broad Institute, Mycobacteria Research Laboratories at Colorado State University, and the University of Chicago to develop a potential new treatment for tuberculosis (TB). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Annature Launches 21 CFR Part 11 Compliant Digital Signatures to Support FDA-Regulated Organisations
Feb 5, 2026 13:00 HKT/SGT
|
|
|
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States
Feb 5, 2026 12:54 HKT/SGT
|
|
|
Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing
Feb 5, 2026 12:53 HKT/SGT
|
|
|
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 5, 2026 11:55: JST
|
|
|
SuperX Strengthens Japan Presence to Explore AI Data Center Projects with Local Partners
Feb 5, 2026 11:00 HKT/SGT
|
|
|
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 5, 2026 10:55 HKT/SGT
|
|
|
雲頂新耀宣佈與麥科奧特達成MT1013獨家商業化許可協議
Feb 5, 2026 10:55 HKT/SGT
|
|
|
云顶新耀宣布与麦科奥特达成MT1013独家商业化许可协议
Feb 5, 2026 10:55 HKT/SGT
|
|
|
Hitachi significantly expands exhibits at the "Hitachi Building Solutions Lab", a research facility for collaborative creation with customers
Feb 5, 2026 11:48 JST
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES, 체외 진단약 등 각종 검사 키트 위탁 제조를 위한 토탈 솔루션 체계 구축
Feb 5, 2026 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES在接受委託製造體外診斷試劑等各種檢驗套組中 確立綜合式的解決方案體制
Feb 5, 2026 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES在体外诊断试剂等的各种检测试剂盒的受托制造中 确立全面解决方案体制
Feb 5, 2026 10:00 HKT/SGT
|
|
|
愛格法醫療榮獲2026年KLAS(R)評鑑美國三大企業影像領域最佳供應商殊榮
Feb 5, 2026 05:00 HKT/SGT
|
|
|
爱克发医疗荣膺2026年KLAS(R)美国三大企业影像领域最佳供应商
Feb 5, 2026 05:00 HKT/SGT
|
|
|
Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing
Feb 4, 2026 23:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
